Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia.

BMC Psychiatry
Haya Ascher-SvanumBruce J Kinon

Abstract

Individuals with schizophrenia may have a higher risk of encounters with the criminal justice system than the general population, but there are limited data on such encounters and their attendant costs. This study assessed the prevalence of encounters with the criminal justice system, encounter types, and the estimated cost attributable to these encounters in the one-year treatment of persons with schizophrenia. This post-hoc analysis used data from a prospective one-year cost-effectiveness study of persons treated with antipsychotics for schizophrenia and related disorders in the United States. Criminal justice system involvement was assessed using the Schizophrenia Patients Outcome Research Team (PORT) client survey and the victimization subscale of the Lehman Quality of Life Interview (QOLI). Direct cost of criminal justice system involvement was estimated using previously reported costs per type of encounter. Patients with and without involvement were compared on baseline characteristics and direct annual health care and criminal justice system-related costs. Overall, 278 (46%) of 609 participants reported at least 1 criminal justice system encounter. They were more likely to be substance users and less adherent to antipsyc...Continue Reading

References

Jul 1, 1989·Hospital & Community Psychiatry·B H McFarlandJ D Bray
Jul 1, 1987·The American Journal of Psychiatry·A Jacobson, B Richardson
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Feb 1, 1984·The American Journal of Psychiatry·A F Lehman, L S Linn
Jan 1, 1995·Schizophrenia Bulletin·P J Weiden, M Olfson
Jan 16, 1999·Psychiatric Services : a Journal of the American Psychiatric Association·V A HidayH R Wagner
May 20, 1999·Psychiatric Services : a Journal of the American Psychiatric Association·R E ClarkG J McHugo
Apr 30, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Matthew J ByerlyJason Hawkins
Jul 29, 2004·Schizophrenia Bulletin·Martin KnappJudit Simon
Jan 12, 2005·The Journal of Clinical Psychiatry·Jeffrey W SwansonRichard A Van Dorn
Feb 11, 2005·Psychiatric Services : a Journal of the American Psychiatric Association·Matthew T Theriot, Steven P Segal
Sep 29, 2005·The Journal of Clinical Psychiatry·Eric Q WuJyoti Aggarwal
Apr 22, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Sandra L TunisRalph Aquila
May 3, 2006·The Journal of Clinical Psychiatry·Haya Ascher-SvanumJeff W Swanson
May 3, 2006·Archives of General Psychiatry·Jeffrey W SwansonJeffrey A Lieberman
Aug 14, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Jeffrey W SwansonUNKNOWN CATIE investigators
Sep 16, 2008·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·S MorrisN Bosanquet
Dec 3, 2008·The American Journal of Psychiatry·Jacques BaillargeonOwen J Murray

❮ Previous
Next ❯

Citations

Apr 30, 2014·Schizophrenia Bulletin·W Wolfgang FleischhackerPeter Woodruff
May 3, 2013·Administration and Policy in Mental Health·Thomas E SmithBradley D Stein
Sep 5, 2013·International Journal of Speech-language Pathology·Jeanne MarshallPamela Dodrill
Apr 28, 2018·PharmacoEconomics·Mark Pennington, Paul McCrone
Sep 13, 2011·American Journal on Intellectual and Developmental Disabilities·Carl V TylerAnil K Jain
Jun 24, 2017·The Psychiatric Quarterly·Kathleen PatchanDeanna L Kelly
Jul 28, 2020·International Journal of Technology Assessment in Health Care·Luca M M JanssenUNKNOWN PECUNIA group
May 24, 2017·PharmacoEconomics·Mark Pennington, Paul McCrone
May 16, 2017·Psychiatry, Psychology, and Law : an Interdisciplinary Journal of the Australian and New Zealand Association of Psychiatry, Psychology and Law·Melissa LaVanWilliam M Marty Martin
Jun 24, 2017·Schizophrenia Bulletin·Stefanie N RezansoffJulian M Somers
Oct 14, 2020·Early Intervention in Psychiatry·Olajumoke M OlogunduduKelly K Anderson
Jul 18, 2021·The Lancet. Psychiatry·Allen Frances

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here